Akụkọ

  • Ntụle mgbe ị na-ewere Ruxolitinib maka oge mbụ

    Ruxolitinib bụ ụdị ọgwụ kansa ezubere iche.A na-eji ya eme ihe iji gbochie mmalite nke ụzọ akara JAK-STAT ma wedata akara ngosi nke na-egbochi nkwalite ahụ na-adịghị mma, si otú a na-enweta ọgwụgwọ ọgwụgwọ.Ọ na-arụ ọrụ site na ...
    GỤKWUO
  • Ruxolitinib significantly reduces disease and improves quality of life in patients

    Ruxolitinib na-ebelata ọrịa nke ukwuu ma mee ka ndụ dịkwuo mma na ndị ọrịa

    Usoro ọgwụgwọ maka myelofibrosis bụ isi (PMF) dabere na stratification ihe ize ndụ.N'ihi ngosipụta dị iche iche nke ụlọ ọgwụ na okwu ndị a ga-eleba anya na ndị ọrịa PMF, usoro ọgwụgwọ kwesịrị ịbanye na ...
    GỤKWUO
  • Ruxolitinib has promising efficacy in myeloproliferative diseases

    Ruxolitinib nwere mmetụta dị mma na ọrịa myeloproliferative

    Ruxolitinib, nke a makwaara dị ka ruxolitinib na China, bụ otu n'ime "ọgwụ ọhụrụ" nke edepụtara n'ọtụtụ ebe na ntuziaka ụlọ ọgwụ maka ọgwụgwọ ọrịa hematological n'afọ ndị na-adịbeghị anya, ma gosi na ọ dị irè na ọrịa myeloproliferative.Ọgwụ ezubere iche...
    GỤKWUO
  • Heart disease needs a new drug – Vericiguat

    Ọrịa obi chọrọ ọgwụ ọhụrụ - Vericiguat

    Ọkpụkpụ obi na mbelata ejection fraction (HFrEF) bụ isi ụdị nkụda mmụọ, na China HF Nnyocha gosiri na 42% nke nkụda mmụọ obi na China bụ HFrEF, n'agbanyeghị na ọtụtụ ọkọlọtọ ọgwụgwọ klas dị maka HFrEF ma belata ihe ize ndụ. nke...
    GỤKWUO
  • Targeted drug for the treatment of myelofibrosis: Ruxolitinib

    Ezubere iche ọgwụ maka ọgwụgwọ nke myelofibrosis: Ruxolitinib

    A na-akpọ Myelofibrosis (MF) dị ka myelofibrosis.Ọ bụkwa ọrịa na-adịghị ahụkebe.Na ihe kpatara ya pathogenesis amaghị.Ngosipụta ụlọ ọgwụ a na-ahụkarị bụ mkpụrụ ndụ ọbara uhie na-eto eto na ụmụntakịrị granulocytic anaemia nwere ọnụ ọgụgụ dị elu nke anya mmiri na-adaba mkpụrụ ndụ ọbara uhie.
    GỤKWUO
  • You should know at least these 3 points about rivaroxaban

    Ị kwesịrị ịma ma ọ dịkarịa ala isi ihe atọ ndị a gbasara rivaroxaban

    Dị ka ọgwụ mgbochi ọnụ ọhụrụ, a na-eji rivaroxaban eme ihe n'ọtụtụ ebe na mgbochi na ọgwụgwọ ọrịa thromboembolic venous na mgbochi ọrịa strok na-abụghị valvular atrial fibrillation.Iji jiri rivaroxaban mee ihe nke ọma, ị kwesịrị ịma ma ọ dịkarịa ala isi ihe atọ ndị a....
    GỤKWUO
  • Changzhou Pharmaceutical received approval to produce Lenalidomide Capsules

    Changzhou Pharmaceutical nwetara nkwado iji mepụta Capsules Lenalidomide

    Changzhou Pharmaceutical Factory Ltd., onye enyemaka nke Shanghai Pharmaceutical Holdings, natara akwụkwọ ndebanye aha ọgwụ ọjọọ (Asambodo Mba 2021S01077, 2021S01078, 2021S01078, 2021S01079) nyere site na State Drug Administration maka Lenali5mgide.
    GỤKWUO
  • What are the precautions for rivaroxaban tablets?

    Kedu ihe kpachara anya maka mbadamba nkume Rivaroxaban?

    Rivaroxaban, dị ka ọgwụ mgbochi ọrịa ọnụ ọhụrụ, ejirila ya mee ihe n'ọtụtụ ebe na mgbochi na ọgwụgwọ nke ọrịa thromboembolic venous.Kedu ihe m kwesịrị ịṅa ntị na mgbe ị na-ewere rivaroxaban?N'adịghị ka warfarin, rivaroxaban anaghị achọ nleba anya nke mkpụkọ ọbara na-egosi ...
    GỤKWUO
  • 2021 FDA kwadoro ọgwụ ọhụrụ 1Q-3Q

    Ihe ọhụrụ na-akwalite ọganihu.Mgbe a bịara n'ihe ọhụrụ na mmepe nke ọgwụ ọhụrụ na ngwaahịa ọgwụgwọ ọgwụgwọ, FDA's Center for Drug Evaluation and Research (CDER) na-akwado ụlọ ọrụ ọgwụ na usoro ọ bụla.Na nghọta ya nke ...
    GỤKWUO
  • Recent developments of Sugammadex Sodium in the wake period of anesthesia

    Mmelite nke Sugammadex Sodium na nso nso a n'oge anesthesia

    Sugammadex Sodium bụ onye mmegide ọhụụ nke ndị na-ahụ maka ahụ ike na-adịghị emebi emebi (myorelaxants), bụ nke mbụ a kọrọ na mmadụ na 2005 ma ejirila ya mee ihe na ụlọ ọgwụ na Europe, United States na Japan.Tụnyere ọgwụ anticholinesterase ọdịnala...
    GỤKWUO
  • Which tumors are thalidomide effective in treating!

    Kedu etuto ndị thalidomide dị irè n'ịgwọ!

    Thalidomide dị irè n'ịgwọ etuto ndị a!1. Na nke siri ike etuto nwere ike iji thalidomide.1.1.ọrịa cancer akpa ume.1.2.Ọrịa prostate.1.3.nodal rectal cancer.1.4.hepatocellular carcinoma.1.5.Ọrịa kansa afọ....
    GỤKWUO
  • Tofacitinib Citrate

    Citrate nke Tofacitinib

    Tofacitinib citrate bụ ọgwụ ndenye ọgwụ (aha azụmaahịa Xeljanz) nke Pfizer mepụtara maka otu klas Janus kinase (JAK) inhibitors.Ọ nwere ike họrọ igbochi JAK kinase, gbochie ụzọ JAK/STAT, wee si otú a gbochie ntụgharị mkpụrụ ndụ ihe nketa na mkpụrụ ndụ ihe jikọrọ ya na ịgbalite ...
    GỤKWUO
12Ọzọ >>> Peeji nke 1/2